Related Experiment Video
Updated: May 16, 2026

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
Published on: May 11, 2020
[Immune efficacy of rabies virus glycoprotein expressed by baculovirus vector]
Qi Chen1, Shou-Feng Zhang, Ye Liu
1Military Veterinary Research Institute, Academy of Military Medical Sciences, Key Laboratory of Jilin Province for Zoonosis Control and Prevention, Changchun 130122, China. chenqi19880804@163.com
Abstract:
To construct a recombinant baculovirus expressing glycoprotein (GP) of RV SRV9 strain and test the immunological efficacy in mice, open reading frame of rabies virus GP gene of SRV9 strain was cloned into the shuttle vector Bacmid to construct the recombinant shuttle plasmid Bacmid-G and transfection was performed into S f9 cells with the recombinant shuttle plasmid. CPE appeared in cell cultures was identified by electronmicroscopy. Western-blot, IFA and immunity tests in mice were performed to identify the immunoreactivity and immunogenicity of the expression products. Our results showed a recombinant baculovirus expressing GP protein of rabies virus SRV9 was obtained. The expression products possessed a favorable immunogenicity and fall immunized mice could develop 100% protective level of anti-rabies neutralizing antibody. In conclusion, The SRV9 glycoprotein expressed by the recombinant baculovirus in this study had good immunogenicity and could induce anti-rabies neutralizing antibody, which laid the foundation of further development of rabies subunit vaccine.

